Role of Biomarkers in Asthma
Experts outline biomarkers to measure asthma, highlighting eosinophil count and fractional exhaled nitric oxide levels.
Read More
Trends in Biologic Treatment of Asthma
Experts discuss the use of biologic treatment in asthma by primary care physicians vs pulmonology specialists as well as overcoming barriers to biologic use through patient and physician education.
Switching Biologic Treatment in Asthma
Experts comment on switching from 1 biologic treatment to another, as well as combining biologics with steroids or other treatments in asthma.
Optimizing Biologic Treatment Selection in Asthma
Andrew White, MD, discusses choosing the right biologic for patients with severe asthma, considering factors such as asthma comorbidities as well as patient preference.
Use of Dupilumab in Treatment of Asthma
Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the efficacy and safety of dupilumab for the treatment of asthma, as well as which patients are good candidates for dupilumab.
Dual Inhibition of Interleukins by Dupilumab in Asthma
Nicole Chase, MD, FAAP, FACAAI, FAAAAI, provides an overview of the difference between single and dual inhibition of interleukins, focusing on dupilumab as a dual inhibitor for asthma treatment.
Use of Biologic Treatment in Asthma
Experts discuss the use of biologic agents to manage asthma and describe the mechanisms of action of different biologics.
Overuse of Oral Corticosteroids in Asthma
Medical expert highlights the risk of overuse of oral corticosteroids in the management of asthma and reviews alternative treatment options.
Use of Guidelines to Classify Asthma
Andrew White, MD, reviews the definition of difficult-to-treat or severe asthma as outlined in the GINA (Global Initiative for Asthma) guidelines.
Treatment Selection for Severe Asthma
Experts discuss the process of choosing a treatment plan for patients with severe allergic or eosinophilic asthma.
Treatment Landscape of Asthma
Andrew White, MD, provides an overview of the asthma treatment landscape, focusing on inhaled and oral corticosteroids, as well as biologic and nonbiologic agents.
Predicting Exacerbation of Asthma
Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the tools available to predict the exacerbation of asthma, highlighting spirometry and biomarkers as effective tools
Signs of Severe Asthma and the Underlying Pathophysiology
Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the symptoms of coughing, wheezing, and shortness of breath as a product of an overactive immune system and as a sign of asthma.
Role of Type 2 Inflammation in Asthma
Nicole Chase, MD, FAAP, FACAAI, FAAAAI, describes the mechanism of type 2 inflammation and comments on it being a prominent issue among patients with asthma.
Overview of Asthma
Andrew White, MD, provides an overview of the difference of asthma endotypes and phenotypes as a way to define and diagnose asthma.
Final Thoughts on Management of Nasal Polyposis
Drs Anju Peters, Naveen Bhandarkar, Andrew White, and Dareen Siri share takeaway thoughts on the management of nasal polyposis.
Unmet Needs in Nasal Polyposis
Drs Anju Peters, Naveen Bhandarkar, Andrew White, and Dareen Siri review unmet needs and shared decision making in the treatment of nasal polyposis.
Emerging Treatment Options for Nasal Polyposis
A multidisciplinary panel reviews emerging treatment options for nasal polyposis, including EDS-FLU, Tezepelumab, and Rimegepant.
Use of Clinical Trials for Patients with Nasal Polyps
Drs Anju Peters and Naveen Bhandarkar, comment on the challenges of using biologic therapies to treat patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).
Challenges in the Use of Biologics for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Biologics for Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
A panel of experts highlights the role of biologics in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
Changing Treatment for Patients with Nasal Polyps
Drs Anju Peters, Naveen Bhandarkar, Andrew White, and Dareen Siri discuss their approach to changing treatment for patients with chronic rhinosinusitis either with or without nasal polyps.
Role of EDS-FLU in Clinical Practice in Nasal Polyposis
A multidisciplinary panel discusses the role of EDU-FLU in their individual practices.
Use of Steroids After Surgery in Nasal Polyposis
Drs Anju Peters and Naveen Bhandarkar comment on the use of steroids after surgery for nasal polyposis.
EDS-PLU Studies for Treatment of Nasal Polyposis
Expert allergists provide an overview of the phase 3 studies with EDS-FLU for treatment of nasal polyposis.
Use of Steroid Eluting Stents in Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Naveen Bhandarkar, MD, shares his thoughts on the role of steroid eluting stents in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
Bioabsorbable Sinus Implants for Nasal Polyposis
Naveen Bhandarkar, MD, discusses the use of sinus implants for the treatment of nasal polyposis.
Large Volume Corticosteroid Delivery System for Nasal Polyposis
Andrew White, MD, reviews large volume corticosteroid delivery devices for patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
Small Volume Corticosteroid Delivery Systems for Nasal Polyposis
Dareen Siri, MD, FAAAAI, FACAAI, highlights small volume corticosteroid delivery systems for patients with nasal polyps and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
Treatment Options for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Dareen Siri, MD, FAAAAI, FACAAI, discusses the treatment options available for Nasal Polyposis.